What's in Bausch Health Companies Inc.'s pipeline?

Bausch Health Companies Inc. has 32 drugs in our index: 32 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Bausch Health Companies Inc.'s portfolio?

Top competitors by shared drug class: , Pfizer, Novartis, AbbVie, Carolina Eyecare Physicians, LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bausch.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Bausch Health Companies Inc. — Portfolio Competitive Intelligence Brief

Bausch Health Companies Inc. (BHC) pipeline: 32 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

BHC (NYSE) 32 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Miebo	PERFLUOROHEXYLOCTANE	marketed	Semifluorinated Alkane [EPC]		Ophthalmology	2023-01-01
Loteprednol Etabonate	LOTEPREDNOL	marketed			Immunology	2020-01-01
Vyzulta	LATANOPROSTENE BUNOD	marketed		Prostaglandin F2-alpha receptor	Cardiovascular	2017-01-01
Xiidra	LIFITEGRAST	marketed	Lymphocyte Function-Associated Antigen-1 Antagonist [EPC]	Intercellular adhesion molecule 1	Immunology	2016-01-01
Jublia	EFINACONAZOLE	marketed	Azole Antifungal [EPC]		Infectious Disease	2014-01-01
Luzu	LULICONAZOLE	marketed	Azole Antifungal [EPC]		Infectious Disease	2013-01-01
Besivance	BESIFLOXACIN	marketed	Quinolone Antimicrobial [EPC]		Infectious Disease	2009-01-01
Bepreve	BEPOTASTINE	marketed	Histamine-1 Receptor Antagonist	H1-receptor, mast cells	Other	2009-01-01
Xenazine	TETRABENAZINE	marketed	Vesicular Monoamine Transporter 2 Inhibitor [EPC]	Synaptic vesicular amine transporter	Metabolic	2008-01-01
Xibrom	BROMFENAC	marketed	Nonsteroidal Anti-inflammatory Drug	Prostaglandin G/H synthase 2	Ophthalmology	2005-01-01
Macugen	pegaptanib	marketed		Vascular endothelial growth factor A	Ophthalmology	2004-01-01
Elidel	PIMECROLIMUS	marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	Peptidyl-prolyl cis-trans isomerase FKBP1A	Immunology	2001-01-01

Therapeutic area mix

Oncology · 7
Immunology · 6
Metabolic · 4
Cardiovascular · 3
Infectious Disease · 3
Neuroscience · 3
Ophthalmology · 3
Other · 2
Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2027-09-02 — Xifaxan · 8193196 · Compound · US
2029-02-26 — Xifaxan · 10456384 · Method of Use · US
2029-02-26 — Xifaxan · 11564912 · Method of Use · US
2029-02-26 — Xifaxan · 11779571 · Method of Use · US
2029-02-26 — Xifaxan · 10765667 · Method of Use · US
2029-07-18 — Xifaxan · 8309569 · Method of Use · US
2029-07-24 — Xifaxan · 10314828 · Method of Use · US
2029-07-24 — Xifaxan · 9629828 · Method of Use · US
2029-07-24 — Xifaxan · 7928115 · Method of Use · US
2029-07-24 — Xifaxan · 10335397 · Method of Use · US
2029-07-24 — Xifaxan · 10709694 · Method of Use · US
2029-07-24 — Xifaxan · 8946252 · Method of Use · US
2029-07-24 — Xifaxan · 9421195 · Method of Use · US
2029-07-24 — Xifaxan · 8829017 · Method of Use · US
2029-08-18 — Aldara · 10238645 · Method of Use · US
2029-08-18 — Aldara · 8598196 · Method of Use · US
2029-10-02 — Xifaxan · 8642573 · Method of Use · US
2029-10-02 — Xifaxan · 8969398 · Method of Use · US
2029-12-11 — Aldara · 8299109 · Method of Use · US
2029-12-11 — Aldara · 8236816 · Method of Use · US
2029-12-11 — Aldara · 8222270 · Method of Use · US
2029-12-11 — Aldara · 11318130 · Method of Use · US
2029-12-11 — Aldara · 10238644 · Method of Use · US
2030-04-30 — Aldara · 11850245 · Method of Use · US
2030-04-30 — Aldara · 10918635 · Method of Use · US
2030-04-30 — Aldara · 11202752 · Method of Use · US
2033-05-03 — Lotemax · 10688045 · Formulation · US
2033-05-03 — Lotemax · 12115246 · Formulation · US
2033-05-03 — Lotemax · 10993908 · Method of Use · US
2033-05-03 — Lotemax · 9827191 · Formulation · US

Competitive overlap (companies sharing drug classes)

· 13 shared drug classes
Pfizer · 6 shared drug classes
Novartis · 2 shared drug classes
AbbVie · 2 shared drug classes
Carolina Eyecare Physicians, LLC · 2 shared drug classes
Padagis LLC · 2 shared drug classes
Merck & Co. · 2 shared drug classes
Sanofi · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Bausch Health Companies Inc.:

Cite this brief

Drug Landscape (2026). Bausch Health Companies Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bausch. Accessed 2026-05-13.